Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.78B |
| 2 |
Microsoft
MSFT
|
+$2.22B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.67B |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.65B |
| 5 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.19B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.45B |
| 2 |
iShares US Real Estate ETF
IYR
|
+$533M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$410M |
| 4 |
Stellantis
STLA
|
+$312M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$240M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.28% |
| 2 | Healthcare | 11.27% |
| 3 | Financials | 10.52% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PINE
3601
Alpine Income Property Trust
PINE
$333M
| $59K | ﹤0.01% |
3,628
-7,774
| -68% | -$124K |
|
3602
Rigel Pharmaceuticals
RIGL
$681M
| $58.7K | ﹤0.01% |
4,550
-5,321
| -54% | -$71.9K |
|
|
SCPH
3603
DELISTED
scPharmaceuticals
SCPH
| $58.7K | ﹤0.01% |
5,756
-67,692
| -92% | -$706K |
|
|
LUNA
3604
DELISTED
Luna Innovations Incorporated
LUNA
| $58.5K | ﹤0.01% |
6,414
-14,239
| -69% | -$113K |
|
3605
First Western Financial
MYFW
$304M
| $58.4K | ﹤0.01% |
3,142
-2,422
| -44% | -$42.5K |
|
|
JBIO
3606
Jade Biosciences
JBIO
$1.2B
| $58.4K | ﹤0.01% |
97
-38
| -28% | -$24.3K |
|
3607
US Global Investors
GROW
$35.5M
| $58.4K | ﹤0.01% |
19,083
| – | – |
|
3608
Atlas Energy Solutions
AESI
$1.35B
| $58K | ﹤0.01% |
3,342
-8,851
| -73% | -$154K |
|
3609
Atea Pharmaceuticals
AVIR
$376M
| $57.1K | ﹤0.01% |
15,271
-23,488
| -61% | -$87.9K |
|
3610
Clover Health Investments
CLOV
$2.2B
| $57.1K | ﹤0.01% |
63,644
-172,612
| -73% | -$153K |
|
|
PSTX
3611
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $57K | ﹤0.01% |
32,368
-70,177
| -68% | -$179K |
|
3612
Atara Biotherapeutics
ATRA
$75.5M
| $56.9K | ﹤0.01% |
1,414
-14,609
| -91% | -$826K |
|
3613
Innodata
INOD
$2.05B
| $56.9K | ﹤0.01% |
5,022
-12,365
| -71% | -$115K |
|
|
INZY
3614
DELISTED
Inozyme Pharma
INZY
| $56.8K | ﹤0.01% |
10,205
+3,932
| +63% | +$23.2K |
|
|
NCTY
3615
The9 Ltd
NCTY
$68.1M
| $56.8K | ﹤0.01% |
7,600
| – | – |
|
3616
Build-A-Bear
BBW
$425M
| $56.7K | ﹤0.01% |
2,649
-22,544
| -89% | -$493K |
|
3617
Seanergy Maritime Holdings
SHIP
$379M
| $56.7K | ﹤0.01% |
11,763
| – | – |
|
3618
First United
FUNC
$285M
| $56.4K | ﹤0.01% |
3,954
+375
| +10% | +$5.54K |
|
|
BLFY
3619
DELISTED
Blue Foundry Bancorp
BLFY
| $56.2K | ﹤0.01% |
5,560
-7,300
| -57% | -$70.4K |
|
3620
First Northwest Bancorp
FNWB
$109M
| $56.2K | ﹤0.01% |
4,939
| – | – |
|
3621
Precigen
PGEN
$2.24B
| $56.2K | ﹤0.01% |
48,856
-34,635
| -41% | -$40.9K |
|
|
BNT
3622
Brookfield Wealth Solutions
BNT
$11.8B
| $56K | ﹤0.01% |
+2,480
| New | +$53.1K |
|
3623
Genie Energy
GNE
$367M
| $55.9K | ﹤0.01% |
3,956
-8,440
| -68% | -$125K |
|
3624
ACNB Corp
ACNB
$656M
| $55.7K | ﹤0.01% |
1,680
-2,516
| -60% | -$78.1K |
|
3625
Chemung Financial Corp
CHMG
$393M
| $55.7K | ﹤0.01% |
1,450
+144
| +11% | +$5.49K |
|
Similar funds
Barclays's Q2 2023 Portfolio in Review
As of Q2 2023, Barclays held 5,371 positions worth $158B, down 28% from $218B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays withdrew a net $70.1B in Q2 2023, closing 872 positions and reducing 1,669 holdings. Its most notable exit was DCP Midstream, LP, an estimated $47.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 12% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Barclays opened a new position in State Street SPDR Nuveen ICE Municipal Bond ETF worth $36.9M.
- Barclays's largest Q2 2023 buy was State Street SPDR Nuveen ICE Municipal Bond ETF: 799,988 shares worth $36.9M.
- Barclays added most to Apple in Q2 2023, an estimated $2.78B increase.
- Barclays's biggest Q2 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.45B.
- Barclays fully exited DCP Midstream, LP in Q2 2023, selling an estimated $47.3M.
- Barclays's ten largest holdings make up 24% of its $158B portfolio in Q2 2023.
- Barclays opened 314 new positions and closed 872 in Q2 2023.
- Barclays's portfolio value fell 28% quarter-over-quarter to $158B.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.